RegCell
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
Epigenetic reprogramming platform for antigen-specific immune-tolerance, 70M+ non-dilutive financing, founded by 2025 Nobel Laureate Shimon Sakaguchi:
RegCell is developing a non-viral, non-gene-edited cell epigenetic reprogramming platform that converts patients' disease-driving CD4⁺ T cells into stable, antigen-specific regulatory T cells (Tregs) with curative potential. Unlike polyclonal Treg expansion or CAR-Tregs, which require indication-specific engineering, RegCell’s approach epigenetically imprints Treg programs (e.g., CNS2/TSDR) to support lineage-stable functional persistence and durable, antigen-specific immune tolerance. Because reprogrammed cells retain their native TCR specificity, the platform enables the precise suppression of disease-causing immune cells, even when causative antigens are multiple or unknown, using a single CMC backbone that is amenable to automation and scalability.
Company HQ City:
Emeryville
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
RC-101
CEO
Michael McCullar, PhD, MBA
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
1H 2028
What is your next catalyst (value inflection) update?
Early POC from RC-101 FIH Study
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}